Global prevalence of antidepressant drug utilization in the community: protocol for a systematic review. Issue 5 (31st May 2022)

• Record Type: Journal Article
• Authors: Lunghi, Carlotta; Dugas, Michèle; Leclerc, Jacinthe; Poluzzi, Elisabetta; Martineau, Cathy; Carnovale, Valérie; Stéfan, Théo; Blouin, Patrick; Lépine, Johanie; Jalbert, Laura; Espinoza Suarez, Nataly R; Svyntozelska, Olha; Dery, Marie-Pier; Ekanmian, Giraud; Nogueira, Daniele Maria; Akinola, Pelumi Samuel; Turcotte, Stéphane; Skidmore, Becky; LeBlanc, Annie
• Is Part Of: BMJ open. Volume 12:Issue 5(2022)
• Publication Date: 2022-05-31
• Subjects: epidemiology -- mental health -- depression & mood disorders -- public health -- therapeutics -- anxiety disorders; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2022-062197
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Antidepressant drugs are the most frequently prescribed medication for mental disorders. They are also used off-label and for non-psychiatric indications. Prescriptions of antidepressants have increased in the last decades, but no systematic review exists on the extent of their use in the community. Methods and analysis: We will conduct a systematic review to estimate the prevalence of antidepressant use in the community. We will search for studies published from 1 January 2010 in the Embase and MEDLINE databases using a combination of controlled vocabulary and keywords adjusted for each database without any language restriction. The main inclusion criterion is the presence of prevalence data of antidepressant utilization. Thus, we will include all studies with a descriptive observational design reporting the prevalence of antidepressant use in the community. Study selection (by title/abstract and full-text screening) and data extraction for included studies will be independently conducted by pairs of reviewers. We will then synthesize the data on the prevalence of antidepressant use in individuals living in the community. If possible, we will perform a meta-analysis to generate prevalence-pooled estimates. If the data allows it, we will conduct subgroup analyses by antidepressant class, age, sex, country and other sociodemographic categories. We will evaluate the risk of bias for each included study through a quality assessment using the Joanna Briggs Institute Critical Appraisal tool: Checklist for Studies Reporting Prevalence Data. DistillerSR software will be used for the management of this review. Ethics and dissemination: Ethical approval is not required for this review as it will not directly involve human or animal subjects. The findings of our systematic review will be disseminated through publications in peer-reviewed journals, the Qualaxia Network (https://qualaxia.org ), presentations at international conferences on mental health and pharmacoepidemiology, as well as general public events. PROSPERO registration number: CRD42021247423.